Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRBP Corbus Pharmaceuticals

Pre-Mkt 04-30 07:56:57 EDT

9.82

+0.00

0.00%

盘前10.05

+0.23+2.34%

07:31 EDT

High10.50	Low9.61	Vol364.42K
Open10.29	D1 Closing9.82	Amplitude9.06%
Mkt Cap174.17M	Tradable Cap125.18M	Total Shares17.74M
T/O3.62M	T/O Rate2.86%	Tradable Shares12.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals","latestPrice":9.82,"timestamp":1777492800000,"preClose":9.82,"halted":0,"volume":364416,"hourTrading":{"tag":"盘前","latestPrice":10.05,"preClose":9.82,"latestTime":"07:31 EDT","volume":5,"amount":50.25,"timestamp":1777548682762,"change":0.23,"changeRate":0.023422,"amplitude":0},"delay":0,"changeRate":0,"floatShares":12747900,"shares":17736464,"eps":-5.899999,"marketStatus":"Pre-Mkt","change":0,"latestTime":"04-30 07:56:57 EDT","open":10.29,"high":10.5,"low":9.61,"amount":3617641.0832640002,"amplitude":0.090631,"askPrice":10.2,"askSize":50,"bidPrice":10,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-5.899999,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777555800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.82,"preHourTrading":{"tag":"盘前","latestPrice":10.05,"preClose":9.82,"latestTime":"07:31 EDT","volume":5,"amount":50.25,"timestamp":1777548682762,"change":0.23,"changeRate":0.023422,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":10.01,"preClose":9.82,"latestTime":"19:58 EDT","volume":1795,"amount":17745.0852,"timestamp":1777507126116,"change":0.19,"changeRate":0.019348,"amplitude":0.019348},"volumeRatio":1.2191358238069814,"impliedVol":0.91,"impliedVolPercentile":0.428},"requestUrl":"/m/hq/s/CRBP","defaultTab":"news","newsList":[{"id":"2631414555","title":"Corbus Pharmaceuticals Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2631414555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631414555?lang=en_us&edition=fundamental","pubTime":"2026-04-30 00:26","pubTimestamp":1777479960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 12:26 ET (16:26 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631621485","title":"U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2631621485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631621485?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:01","pubTimestamp":1777449675,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings April 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"67733c4db6344c7b88c9eccfef6b67cb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL4N41C0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDLZ","BEN","IVZ","LU1978683503.SGD","DVN","CNCG","FFIV","BEX","NBN","BEG","CCS","CDNS","AVY","BRO","BK4211","DSGN","LU0312595415.SGD","FSUN","COTY","CCK","MBIN","GLW","ELF","GM","ARCB","ENPH","BEZ","IPAR","LSTR","BE","AVB","CNC","CVLT","CR","BKNG","BKNU","KO","NMTC","CINF","HLT","HVII","EL","DRVN","LU2764263039.SGD","BBIO","HRI","LU0823411888.USD","CRBP","CHTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631554439","title":"Corbus Pharmaceuticals Holdings Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2631554439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631554439?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:16","pubTimestamp":1777432613,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41B0W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631311575","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2631311575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631311575?lang=en_us&edition=fundamental","pubTime":"2026-04-29 05:21","pubTimestamp":1777411260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slipped 2.58% to $9.82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index  falling 0.90% to 24,663.80 and Dow Jones Industrial Average  falling 0.05% to 49,141.93.Corbus Pharmaceuticals Holdings Inc. closed 52.24% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 0.74% to $6.84, Fortress Biotech Inc.  fell 1.32% to $2.24, and Viking Therapeutics Inc.  fell 1.80% to $32.39.Trading volume  remained 18,531 below its 50-day average volume of 227,575.Data source: Dow Jones Market Data, FactSet. Data compiled April 28, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631296535","title":"Corbus Pharmaceuticals initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2631296535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631296535?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:17","pubTimestamp":1777407432,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Corbus Pharmaceuticals (CRBP) with a Buy rating and $45 price target Published first on TheFly – the ultimate sour...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630200368","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2630200368","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630200368?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:21","pubTimestamp":1777065660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slipped 1.57% to $10.06 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index  rising 1.63% to 24,836.60 and the Dow Jones Industrial Average  falling 0.16% to 49,230.71.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 51.07% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its competitors Friday, as Vanda Pharmaceuticals Inc.  rose 2.99% to $6.89, Fortress Biotech Inc.  rose 4.48% to $2.33, and Viking Therapeutics Inc.  fell 0.15% to $32.75.Trading volume  eclipsed its 50-day average volume of 219,266.Data source: Dow Jones Market Data, FactSet. Data compiled April 24, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629557075","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2629557075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629557075?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:23","pubTimestamp":1776892980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 1.80% to $10.48 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index  rising 1.64% to 24,657.57 and the Dow Jones Industrial Average  rising 0.69% to 49,490.03.Corbus Pharmaceuticals Holdings Inc. closed 49.03% short of its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  rose 0.74% to $6.83, Fortress Biotech Inc.  rose 0.90% to $2.25, and Viking Therapeutics Inc.  rose 1.33% to $34.25.Trading volume  eclipsed its 50-day average volume of 213,478.Data source: Dow Jones Market Data, FactSet. Data compiled April 22, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629046852","title":"Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046852","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629046852?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:00","pubTimestamp":1776859200,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., April  22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today ann","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278900/0/en/Corbus-Pharmaceuticals-Announces-Abstracts-Accepted-for-Presentation-at-ASCO-2026-Featuring-Updated-Clinical-Data-for-CRB-701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP","BK4231","ADC","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629063742","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2629063742","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629063742?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:20","pubTimestamp":1776806400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 3.06% to $10.30 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 0.59% to 24,259.96 and Dow Jones Industrial Average  falling 0.59% to 49,149.38.The stock's fall snapped a three-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 49.93% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  fell 3.00% to $6.78, Fortress Biotech Inc.  fell 3.88% to $2.23, and Viking Therapeutics Inc.  fell 4.87% to $33.80.Trading volume  remained 28,109 below its 50-day average volume of 213,678.Data source: Dow Jones Market Data, FactSet. Data compiled April 21, 2026.This content was created by MarketWatch, which is ope","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628244349","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2628244349","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628244349?lang=en_us&edition=fundamental","pubTime":"2026-04-17 05:22","pubTimestamp":1776374520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 1.40% to $10.14 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 0.36% to 24,102.70 and the Dow Jones Industrial Average  rising 0.24% to 48,578.72.The stock's rise snapped a two-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 50.68% below its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  fell 1.51% to $7.16, Fortress Biotech Inc.  fell 3.29% to $2.35, and Viking Therapeutics Inc.  rose 0.17% to $35.51.Trading volume  remained 27,032 below its 50-day average volume of 201,557.Data source: Dow Jones Market Data, FactSet. Data compiled April 16, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628244310","title":"Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections","url":"https://stock-news.laohu8.com/highlight/detail?id=2628244310","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628244310?lang=en_us&edition=fundamental","pubTime":"2026-04-17 05:12","pubTimestamp":1776373968,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals ( ($CRBP) ) has provided an announcement. On April 15, 2026, Corbus Pharmaceuticals entered into amended and restated employ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corbus-pharmaceuticals-updates-executive-employment-agreements-and-protections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corbus-pharmaceuticals-updates-executive-employment-agreements-and-protections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628924950","title":"Corbus CEO Cohen base salary rises to $673,625 under amended employment agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2628924950","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628924950?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:20","pubTimestamp":1776370839,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals entered amended and restated employment agreements effective April 15, 2026 for Chief Executive Officer Yuval Cohen and Chief Financial Officer Sean Moran.Cohen base salary set at $673,625 with annual bonus target up to 60% of base salary.Moran base salary set at $501,273 with annual bonus target up to 40% of base salary.Severance terms provide 12 months of base salary for Cohen, rising to 24 months during change in control period; Moran severance set at 12 months, rising to 18 months during change in control period.Change in control provisions include accelerated vesting of outstanding equity awards; bonus payout set at 2x target for Cohen, target for Moran.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL9C9h2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627898446","title":"Corbus Pharmaceuticals announces last person enrolled in CANYON-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627898446","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627898446?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:12","pubTimestamp":1776168736,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (CRBP) announced the last patient has been enrolled and completed the first clinical visit in the company’s CANYON-1 Phase 1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-announces-last-person-enrolled-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-announces-last-person-enrolled-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445209","title":"Corbus enrolls last patient in Phase 1b CANYON-1 obesity trial of CRB-913","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445209","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445209?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:11","pubTimestamp":1776168684,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals reported last patient first visit in CANYON-1, a Phase 1b trial of oral obesity drug candidate CRB-913.Study completion remains targeted for summer 2026, with results to be presented in the future.Trial is designed to assess dose selection for a daily non-incretin therapy intended for weight loss and long-term weight management.Corbus positioned CRB-913 as an alternative for patients who cannot tolerate or do not respond to incretin-based obesity drugs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL8c3T4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627454534","title":"Corbus Pharmaceuticals Holdings Inc - Canyon-1 Study on Track for Completion in Summer 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627454534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627454534?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:00","pubTimestamp":1776168006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA7PNFVX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627466426","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2627466426","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627466426?lang=en_us&edition=fundamental","pubTime":"2026-04-14 05:21","pubTimestamp":1776115260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  advanced 3.88% to $10.18 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index  rising 1.23% to 23,183.74 and the Dow Jones Industrial Average  rising 0.63% to 48,218.25.Corbus Pharmaceuticals Holdings Inc. closed 50.49% below its 52-week high of $20.56, which the company achieved on October 20th.The stock outperformed some of its competitors Monday, as Vanda Pharmaceuticals Inc.  fell 0.83% to $7.16, Fortress Biotech Inc.  rose 2.98% to $2.42, and Viking Therapeutics Inc.  rose 2.19% to $35.01.Trading volume  remained 69,119 below its 50-day average volume of 196,927.Data source: Dow Jones Market Data, FactSet. Data compiled April 13, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626504153","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2626504153","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626504153?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:21","pubTimestamp":1775769660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 4.88% to $10.32 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 0.83% to 22,822.42 and the Dow Jones Industrial Average  rising 0.58% to 48,185.80.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 49.81% below its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  rose 0.55% to $7.33, Fortress Biotech Inc.  rose 3.90% to $2.40, and Viking Therapeutics Inc.  rose 3.80% to $34.95.Trading volume  eclipsed its 50-day average volume of 198,952.Data source: Dow Jones Market Data, FactSet. Data compiled April 9, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is pub","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626806881","title":"Analysts Offer Insights on Healthcare Companies: Treace Medical Concepts (TMCI), Corbus Pharmaceuticals (CRBP) and Avita Medical (RCEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626806881","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626806881?lang=en_us&edition=fundamental","pubTime":"2026-04-09 21:10","pubTimestamp":1775740226,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Treace Medical Concepts (TMCI), Corbus Pharmaceuticals (CRBP) and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-treace-medical-concepts-tmci-corbus-pharmaceuticals-crbp-and-avita-medical-rcel-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-treace-medical-concepts-tmci-corbus-pharmaceuticals-crbp-and-avita-medical-rcel-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4581","BK4137","LU0029874061.USD","BK4082","BK4585","LU0128526141.USD","RCEL","BK4539","BK4588","BK4139","TMCI","XBI","LABU","XLV","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626303920","title":"Corbus Pharmaceuticals Holdings Inc. Stock Rises Wednesday, Still Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2626303920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626303920?lang=en_us&edition=fundamental","pubTime":"2026-04-09 05:19","pubTimestamp":1775683140,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 1.34% to $9.84 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 2.80% to 22,635.00 and the Dow Jones Industrial Average  rising 2.85% to 47,909.92.The stock's rise snapped a two-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 52.14% below its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  fell 2.15% to $7.29, Fortress Biotech Inc.  fell 1.70% to $2.31, and Viking Therapeutics Inc.  fell 0.09% to $33.67.Trading volume  eclipsed its 50-day average volume of 198,991.Data source: Dow Jones Market Data, FactSet. Data compiled April 8, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625194654","title":"Corbus Pharmaceuticals (CRBP) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2625194654","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625194654?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:55","pubTimestamp":1775649343,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush reiterated a Buy rating on Corbus Pharmaceuticals, with a price target of $38.00. In addition to Wedbush, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/corbus-pharmaceuticals-crbp-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/corbus-pharmaceuticals-crbp-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":-0.063},{"period":"1month","weight":0.1419},{"period":"3month","weight":0.1379},{"period":"6month","weight":-0.1918},{"period":"1year","weight":0.3639},{"period":"ytd","weight":0.2064}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.197993},{"month":4,"riseRate":0.545455,"avgChangeRate":0.045896},{"month":5,"riseRate":0.636364,"avgChangeRate":0.079186},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.065346},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.050382},{"month":8,"riseRate":0.636364,"avgChangeRate":0.095672},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.086452},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corbus Pharmaceuticals,CRBP,Corbus Pharmaceuticals股票,Corbus Pharmaceuticals股票老虎,Corbus Pharmaceuticals股票老虎国际,Corbus Pharmaceuticals行情,Corbus Pharmaceuticals股票行情,Corbus Pharmaceuticals股价,Corbus Pharmaceuticals股市,Corbus Pharmaceuticals股票价格,Corbus Pharmaceuticals股票交易,Corbus Pharmaceuticals股票购买,Corbus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}